Posted by Michael Wonder on 18 Sep 2025
Anti-MTBR (microtubule binding region) tau antibody etalanetug granted FDA fast track designation
16 September 2025 - Eisai announced today that etalanetug (E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted fast track designation by the US FDA.
Etalanetug is an anti-tau antibody that targets specific tau species containing MTBR, tau seeds that spread tau pathology to different brain regions.
